{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T04:33:24Z","timestamp":1782016404422,"version":"3.54.5"},"reference-count":39,"publisher":"Elsevier BV","issue":"43","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.vaccine.2022.09.020","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T08:45:38Z","timestamp":1663663538000},"page":"6277-6287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunity of two novel hepatitis C virus polyepitope vaccines"],"prefix":"10.1016","volume":"40","author":[{"given":"Tian","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lirong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zibing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lumei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunli","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingbao","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.09.020_b0005","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ijbiomac.2021.08.032","article-title":"Cellular OCIAD2 protein is a proviral factor for hepatitis C virus replication","volume":"188","author":"Yang","year":"2021","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.09.020_b0010","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1128\/CMR.00037-16","article-title":"Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C","volume":"30","author":"Wilson","year":"2017","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"10.1016\/j.vaccine.2022.09.020_b0015","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41575-021-00570-x","article-title":"Vaccination at the forefront of the fight against hepatitis B and C","volume":"19","author":"El-Sayed","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.vaccine.2022.09.020_b0020","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.3390\/pathogens10121619","article-title":"Gish RG","volume":"10","author":"Manne","year":"2021","journal-title":"Pathogens"},{"issue":"7","key":"10.1016\/j.vaccine.2022.09.020_b0025","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/nm.3183","article-title":"Current progress in development of hepatitis C virus vaccines","volume":"19","author":"Liang","year":"2013","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.vaccine.2022.09.020_b0030","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1406011","article-title":"Long-term efficacy of a hepatitis E vaccine","volume":"372","author":"Zhang","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2022.09.020_b0035","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jnci\/djz074","article-title":"Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial","volume":"112","author":"Qiao","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"39","key":"10.1016\/j.vaccine.2022.09.020_b0040","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1016\/j.vaccine.2014.07.011","article-title":"Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers","volume":"32","author":"Low","year":"2014","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2022.09.020_b0045","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.pep.2006.02.013","article-title":"Purification and application of bacterially expressed chimeric protein E1E2 of hepatitis C virus","volume":"49","author":"Xiang","year":"2006","journal-title":"Protein Expr Purif"},{"issue":"11","key":"10.1016\/j.vaccine.2022.09.020_b0050","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/apm.13074","article-title":"Canola oilseed- and Escherichia coli- derived hepatitis C virus (HCV) core proteins adjuvanted with oil bodies, induced robust Th1-oriented immune responses in immunized mice","volume":"128","author":"Mohammadzadeh","year":"2020","journal-title":"APMIS"},{"key":"10.1016\/j.vaccine.2022.09.020_b0055","doi-asserted-by":"crossref","first-page":"105965","DOI":"10.1016\/j.pep.2021.105965","article-title":"Expression of HCV genotype-4 core antigen in prokaryotic E. coli system for diagnosis of HCV infection in Egypt","volume":"188","author":"Saleh","year":"2021","journal-title":"Protein Expr Purif"},{"issue":"20","key":"10.1016\/j.vaccine.2022.09.020_b0060","doi-asserted-by":"crossref","first-page":"7705","DOI":"10.1073\/pnas.0402458101","article-title":"Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma","volume":"101","author":"Yu","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"10.1016\/j.vaccine.2022.09.020_b0065","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1073\/pnas.0607026104","article-title":"Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C","volume":"104","author":"Pestka","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1-2","key":"10.1016\/j.vaccine.2022.09.020_b0070","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jviromet.2010.01.017","article-title":"Immunogenic properties of chimeric potato virus X particles displaying the hepatitis C virus hypervariable region I peptide R9","volume":"166","author":"Uhde-Holzem","year":"2010","journal-title":"J Virol Methods"},{"issue":"2","key":"10.1016\/j.vaccine.2022.09.020_b0075","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s10875-005-2820-4","article-title":"Immunogenic Properties of a Chimeric Plant Virus Expressing a Hepatitis C Virus (HCV)-Derived Epitope: New Prospects for an HCV Vaccine","volume":"25","author":"Piazzolla","year":"2005","journal-title":"J Clin Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2022.09.020_b0080","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.jhep.2010.09.040","article-title":"Progress in the development of preventive and therapeutic vaccines for hepatitis C virus","volume":"54","author":"Torresi","year":"2011","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.vaccine.2022.09.020_b0085","doi-asserted-by":"crossref","first-page":"e00858","DOI":"10.1128\/JVI.00858-19","article-title":"Surfeit 4 Contributes to the Replication of Hepatitis C Virus Using Double-Membrane Vesicles","volume":"94","author":"Kong","year":"2020","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2022.09.020_b0090","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1128\/JVI.01540-15","article-title":"Prolactin Regulatory Element Binding Protein Is Involved in Hepatitis C Virus Replication by Interaction with NS4B","volume":"90","author":"Kong","year":"2016","journal-title":"J Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2022.09.020_b0095","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nm1268","article-title":"Production of infectious hepatitis C virus in tissue culture from a cloned viral genome","volume":"11","author":"Wakita","year":"2005","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.vaccine.2022.09.020_b0100","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1007\/s00705-016-2892-x","article-title":"Hepatitis C virus and its protein NS4B activate the cancer-related STAT3 pathway via the endoplasmic reticulum overload response","volume":"161","author":"Kong","year":"2016","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2022.09.020_b0105","doi-asserted-by":"crossref","first-page":"103353","DOI":"10.1016\/j.ebiom.2021.103353","article-title":"Novel Japanese encephalitis virus NS1-based vaccine: Truncated NS1 fused with E. coli heat labile enterotoxin B subunit","volume":"67","author":"Wan","year":"2021","journal-title":"EBioMedicine"},{"issue":"1-2","key":"10.1016\/j.vaccine.2022.09.020_b0110","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-1759(98)00170-7","article-title":"A statistically defined endpoint titer determination method for immunoassays","volume":"221","author":"Frey","year":"1998","journal-title":"J Immunol Methods"},{"issue":"1","key":"10.1016\/j.vaccine.2022.09.020_b0115","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.antiviral.2013.02.003","article-title":"Oleanolic acid and ursolic acid: novel hepatitis C virus antivirals that inhibit NS5B activity","volume":"98","author":"Kong","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2022.09.020_b0120","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"issue":"1","key":"10.1016\/j.vaccine.2022.09.020_b0125","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0008-8749(86)90385-0","article-title":"Enhancement of intracellular glutathione promotes lymphocyte activation by mitogen","volume":"97","author":"Fidelus","year":"1986","journal-title":"Cell Immunol"},{"key":"10.1016\/j.vaccine.2022.09.020_b0130","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/978-1-4939-0758-8_26","article-title":"Serum virus neutralization assay for detection and quantitation of serum-neutralizing antibodies to influenza A virus in swine","volume":"1161","author":"Gauger","year":"2014","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2022.09.020_b0135","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/978-1-4939-8976-8_29","article-title":"In Vitro Neutralization Assay Using Cultured Hepatitis C Virus","volume":"1911","author":"Prentoe","year":"2019","journal-title":"Methods Mol Biol"},{"issue":"3","key":"10.1016\/j.vaccine.2022.09.020_b0140","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S0016-5085(99)70185-X","article-title":"Real-time detection system for quantification of hepatitis C virus genome","volume":"116","author":"Takeuchi","year":"1999","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.vaccine.2022.09.020_b0145","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3390\/v13050833","article-title":"From Structural Studies to HCV Vaccine Design","volume":"13","author":"Yechezkel","year":"2021","journal-title":"Viruses"},{"issue":"23","key":"10.1016\/j.vaccine.2022.09.020_b0150","doi-asserted-by":"crossref","first-page":"10486","DOI":"10.1128\/JVI.01462-16","article-title":"Altered Glycosylation Patterns Increase Immunogenicity of a Subunit Hepatitis C Virus Vaccine, Inducing Neutralizing Antibodies Which Confer Protection in Mice","volume":"90","author":"Li","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2022.09.020_b0155","doi-asserted-by":"crossref","unstructured":"Donnison T, McGregor J, Chinnakannan S, Hutchings C, Center RJ, Poumbourios P, et al. A pan-genotype hepatitis C virus viral vector vaccine generates T cells and neutralizing antibodies in mice. Hepatology. 2022.","DOI":"10.1002\/hep.32470"},{"issue":"6","key":"10.1016\/j.vaccine.2022.09.020_b0160","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1056\/NEJMoa2023345","article-title":"Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection","volume":"384","author":"Page","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2022.09.020_b0165","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jhep.2021.12.026","article-title":"Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice","volume":"76","author":"Pihl","year":"2022","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.vaccine.2022.09.020_b0170","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01675-21","article-title":"Virus-Like Particles Containing the E2 Core Domain of Hepatitis C Virus Generate Broadly Neutralizing Antibodies in Guinea Pigs","volume":"96","author":"McGregor","year":"2022","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.09.020_b0175","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/gutjnl-2017-314870","article-title":"A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey","volume":"68","author":"Wang","year":"2019","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.vaccine.2022.09.020_b0180","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jviromet.2010.01.021","article-title":"In vitro stability of Cucumber mosaic virus nanoparticles carrying a Hepatitis C virus-derived epitope under simulated gastrointestinal conditions and in vivo efficacy of an edible vaccine","volume":"165","author":"Nuzzaci","year":"2010","journal-title":"J Virol Methods"},{"issue":"5","key":"10.1016\/j.vaccine.2022.09.020_b0185","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00705-006-0916-7","article-title":"Cucumber mosaic virus as a presentation system for a double hepatitis C virus-derived epitope","volume":"152","author":"Nuzzaci","year":"2007","journal-title":"Arch Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.09.020_b0190","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00705-003-0190-x","article-title":"Cucumber mosaic virus as carrier of a hepatitis C virus-derived epitope","volume":"149","author":"Natilla","year":"2003","journal-title":"Arch Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2022.09.020_b0195","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.biotechadv.2009.03.006","article-title":"Plants as bioreactors for the production of vaccine antigens","volume":"27","author":"Tiwari","year":"2009","journal-title":"Biotechnol Adv"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2201115X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2201115X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:18:16Z","timestamp":1759403896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2201115X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":39,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0264410X2201115X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.09.020","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunity of two novel hepatitis C virus polyepitope vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}